Yonghe Medical Group Co., Ltd. (stock code: 2279) announced updates to its Nomination Committee Terms of Reference, reflecting changes approved by the board of directors on October 28, 2025. The Nomination Committee was originally formed on November 24, 2021, and this latest revision further clarifies its composition, roles, and responsibilities.

Under the updated framework, the Nomination Committee must comprise at least three members, including at least one director of a different gender, with a majority of seats held by independent non-executive directors. Its chairman must either be the chairman of the Board or an independent non-executive director. The committee is required to meet at least once a year, with notice periods and quorum requirements outlined in the company’s Articles of Association.

The Terms of Reference stipulate that the Nomination Committee can access management and external professional advisors to evaluate potential candidates and oversee board composition. Its core responsibilities include recommending director appointments, assessing the independence of prospective and existing independent non-executive directors, developing diversity policies, and supporting overall board effectiveness. The Terms of Reference are made available in both English and traditional Chinese, with the English version prevailing in case of any discrepancy.